ArticleViruses2026
Monitoring of RSV-A and RSV-B Circulation in Poland Across Three Post-Pandemic Seasons (2022-2025).
Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparison of the Clinical Course of Viral Respiratory Infections in Hospitalized Patients During the 2025/2026 Season in Poland.Vaccines · 2026Article
- Delineating RSV-A and RSV-B: Epidemiological Patterns, Diagnostics, Clinical Severity, and Preventive Approaches.Journal of medical virology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Respiratory syncytial virus (RSV) is a significant cause of respiratory infections across all ages. However, data on the circulation of its antigenic subgroups, RSV-A and RSV-B, remain limited in certain regions, including Poland. Therefore, this study provides the first molecular insight into the post-pandemic circulation of RSV subgroups in Poland. We analyzed 377 RSV-positive respiratory samples collected across Poland during three consecutive seasons (2022/23, 2023/24, and 2024/25) using qRT-PCR to determine subgroup distribution. An equal prevalence of RSV-A and RSV-B was observed in 2022/23, followed by RSV-A predominance in 2023/24 and a shift to RSV-B dominance in 2024/25. Individuals infected with RSV-A were significantly younger than those infected with RSV-B, a pattern evident in the latter two seasons but not in 2022/23. In general, adults (≥18 years) had higher odds of RSV-B infection (OR = 2.35, 95% CI: 1.44-3.84;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.